(Bloomberg) -- Gilead Sciences Inc. analysts offered a broad range of views on the inadvertently leaked abstract that indicated the company’s remdesivir failed to provide a benefit in a placebo-controlled trial in Chinese patients with severe Covid-19.Skeptical analysts included Baird’s Brian Skorney, who said the negative results “should be very sobering” given the lack of an improvement and argued that the result is “pretty close to a worst case scenario.” Others on Wall Street argued that investors should hold off on jumping to conclusions.“The bottom line is that stating the trial flopped appears overly aggressive and premature, particularly in light of Gilead’s comments,” Piper Sandler analyst Tyler Van Buren said in a note. Gilead shares tumbled 8.5% before erasing some of the losses as investors studied the leaked report.Mizuho analyst Salim Syed was quick to point out that there are “limitations” and negatives from the leaked results, though there are “no...
As a perishable goods fleet, Veritable Vegetable is conscious of not only protecting its drivers and employees during the COVID-19 pandemic, but also checking in on its clients and the growers they work with. ...
How far are we from a viable COVID-19 treatment? Worldwide, over 178,000 people have died so far, with confirmed cases numbering more than 2,500,000. More than 150 drugs are being researched as possible treatments, by companies big and small.Pluristem Therapeutics (PSTI) falls squarely into the latter category. The micro-cap pharma company has been grabbing some attention with its potential COVID-19 treatment.Following a virtual fireside chat with Pluristem’s President and CEO Yaky Yanay, H.C. Wainwright’s Swayampakula Ramakanth noted, “In our view, with the ongoing pandemic affecting nearly every country and stressing healthcare systems around the world, there is an urgent need for new and effective treatments, and this represents a significant market opportunity for Pluristem.” According to Yanay, the analyst said, "The company’s current centralized manufacturing facility in Israel is capable of producing sufficient doses to treat thousands of patients, and more capacity could be allocated to treat COVID-19 as needed.”In March,...
The Financial Times reports Gilead Sciences' coronavirus drug failed its first randomized clinical trial. Yahoo Finance’s Anjalee Khemlani joins Seana Smith to discuss....
While Wedbush sees a difficult short-term trajectory for Apple Inc. (NASDAQ: AAPL), the sell-side firm said Thursday that Cupertino is staying on track with the launch schedule for its flagship product, the iPhone. The Apple Analyst Daniel Ives maintained an Outperform rating on Apple with a $335 price target. What's Known About The iPhone 12 Apple is likely working on four iPhone 12 models, with a mix of 4G and 5G phones that are likely to be launched between October and early December, just in time for the holiday season, Ives said in a Thursday note, citing supply chain checks in Asia. (See his track record here.)The analyst said he expects two versions of 5G phones, U.S. and non-U.S., with the U.S. version likely to have mmWave technology that could push out the production timeline.Many units could therefore be shifted to the March quarter, he said. Muted Expectations For Apple's Q2...
